EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Data-Independent Acquisition Proteomics Identifies Plasma Prostaglandin-H2 D-Isomerase as an Early Diagnostic Biomarker for STEMI and NSTEMI

Hong-Mei Xue, Hai-Tao Hou, Yu Song, Huan-Xin Chen, Yun-Qiang Zhang, Wen-Tao Sun, Jie Zhou, Xiao-Lin Zhou, Na Sun, Qin Yang, Guo-Wei He

Molecular & Cellular Proteomics · 2025-07 · 24 (7) · 100996

DOI: 10.1016/j.mcpro.2025.100996 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2025-07. Verfasst von Hong-Mei Xue und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular Surgery, The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin University & Chin…. Hauptthemen laut MEDLINE: Proteomics, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Intramolecular Oxidoreductases. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Hebei Provincial Natural Science Foundation, Special Fund for High-Quality Development Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial infarction (MI), including ST-segment elevation myocardial infarction (STEMI) and non-ST-segment elevation myocardial infarction (NSTEMI), remains a leading cause of death worldwide. This study aimed to identify the early diagnostic biomarkers for STEMI and NSTEMI. Plasma samples from 386 patients were classified into four groups: control (CON) (n = 62), unstable angina (UA) (n = 62), STEMI (n = 182), and NSTEMI (n = 80). The protein profiles were analyzed using data-independent acquisition (DIA)-based proteomics to identify differentially abundant proteins (DAPs) followed by bioinformatics analysis and ELISA validation. In STEMI, 93 DAPs were detected. Among the selected DAPs that were further validated in a new cohort of patients, prostaglandin-H2 D-isomerase (PTGDS) was elevated at the earliest onset time of STEMI (T1, 1.45 h (95% CI: 1.16-1.73)) or NSTEMI (T1, 1.48 h (95% CI: 0.97-1.98)) while the current biomarkers (hs-TnI, Myo, CK-MB, and BNP) remained within normal ranges. The analysis of diagnostic indices for plasma PTGDS demonstrated a sensitivity of 63.95% and specificity of 65.38% in STEMI, 70% and 71.15% in NSTEMI. Moreover, AUC was 0.61 (95% CI: 0.53-0.69) in STEMI and 0.78 (95% CI: 0.70-0.86) in NSTEMI. The present study demonstrates that in patients with MI, plasma PTGDS increases at an earlier stage of onset time than the current biomarkers, with similar sensitivity and specificity. Therefore, PTGDS has high potential to be developed as an early diagnostic biomarker. In particular, PTGDS might be of greater clinical significance for patients suspected of NSTEMI, for which the biomarker could be more effective in identifying high-risk patients suffering from MI at an early stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ProteomicsST Elevation Myocardial InfarctionNon-ST Elevated Myocardial InfarctionIntramolecular OxidoreductasesLipocalinsHumansMaleBiomarkersFemaleMiddle AgedAgedEarly Diagnosis

Stichwörter der Autor:innen

NSTEMISTEMIacute coronary syndromebiomarkersdata-independent acquisition proteomicsprostaglandin-H2 D-isomerase

Substanzen

BiomarkersIntramolecular Oxidoreductasesprostaglandin R2 D-isomeraseLipocalins

Autor:innen und Institutionen

  • Department of Cardiovascular Surgery, The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin University & Chinese Academy of Medical Sciences, Tianjin, China; Tianjin Key Laborator…
  • Tianjin Key Laboratory of Molecular Regulation of Cardiovascular Diseases and Translational Medicine, Tianjin, China; The Institute of Cardiovascular Diseases, TEDA International Cardiovascular Hospital, Tianjin Univers…

Förderung

  • National Natural Science Foundation of China
  • Hebei Provincial Natural Science Foundation
  • Special Fund for High-Quality Development Project
  • Chinese Academy of Medical Sciences & Peking Union Medical College
  • TEDA International Cardiovascular Hospital
  • Tianjin Municipal Science and Technology Bureau
  • Tianjin Municipal Science and Technology Committee

Zitieren

APA

Xue, H. M., Hou, H. T., Song, Y., Chen, H. X., Zhang, Y. Q., Sun, W. T., Zhou, J., Zhou, X. L., Sun, N., Yang, Q., & He, G. W. (2025). Data-Independent Acquisition Proteomics Identifies Plasma Prostaglandin-H2 D-Isomerase as an Early Diagnostic Biomarker for STEMI and NSTEMI. Molecular & Cellular Proteomics, 24(7), 100996. https://doi.org/10.1016/j.mcpro.2025.100996

Vancouver

Xue HM, Hou HT, Song Y, Chen HX, Zhang YQ, Sun WT, et al. Data-Independent Acquisition Proteomics Identifies Plasma Prostaglandin-H2 D-Isomerase as an Early Diagnostic Biomarker for STEMI and NSTEMI. Molecular & Cellular Proteomics. 2025;24(7):100996. doi:10.1016/j.mcpro.2025.100996

BibTeX
@article{Xue2025,
  author = {Xue, Hong-Mei and Hou, Hai-Tao and Song, Yu and Chen, Huan-Xin and Zhang, Yun-Qiang and Sun, Wen-Tao and Zhou, Jie and Zhou, Xiao-Lin and Sun, Na and Yang, Qin and He, Guo-Wei},
  title = {Data-Independent Acquisition Proteomics Identifies Plasma Prostaglandin-H2 D-Isomerase as an Early Diagnostic Biomarker for STEMI and NSTEMI},
  journal = {Molecular & Cellular Proteomics},
  year = {2025},
  volume = {24},
  number = {7},
  pages = {100996},
  doi = {10.1016/j.mcpro.2025.100996}
}
Kostenlos starten →